Table 3.

Experimental designs of stroke studies – in vivo

Ref	Animal	Sex	Weight (g)	N/G	Animal model				Stem cell						Sacrifice
					Occlusion		Test		Concentration	Im (mg/kg)	Tp (day)	Grafting site	Test		Type	Day
					Type	OT (min)	Mth	Day					Mth	Day
76	Rat SD	N/A	160–180	N/A	MCDA	T 5	NS/MRI	0	3×104	N/A	2	ISt (0.5/3/5)	MRI	1, 7, 21	4% PFA	21
15	Rat	N/A	N/A	N/A	MCDA	T 90	MRI	1 h	107	N/A	90 min	IC	MRI	1 h, 1, 3, 7	4% PFA	7
75	Dog (Beagle)	M	14 kg	14/2	MCDA	T 120	NS AG	2 h	3×106	N/A	2 h	IC	MRI NS	6 h, 17	4% PFA	1, 28
72	Rabbit NZ	M	N/A	16/N/A	OAF	T 5	MRI	1, 21	105 (300 μL)	N/A	5 min	EV	MRI	1, 21	4% PFA	1, 21
77	Rat SD	N/A	N/A	N/A	MCDA	T 30	N/A	N/A	105	N/A	7	ICe	MRI	1, 21	N/A	21
64	Rat SD	M	300	14/3	MCDA	T 90	NS	0	4×105 (7 μL)	N/A	1	ISt (0/3/6) IC ICo (0/3/2)	NS	2,7, 14, 21	4% PFA	1, 15, 28
63	Mice	F	N/A	21/3	MCDA	T 60	MRI	0	105 (5 μL)	N/A	7	ISt (1/1/3) bilat	MRI	1, 7, 30	4% PFA	30
71	Rat SD	M	250–300	60/6	MCDA CCO	P or T 30	NS	0, 1, 14	2×106 (650 μL)	N/A	1	IC EV	NS, MRI	0, 1, 14	4% PFA	14
14	Rat Fisher	M	N/A	N/A	FOT1	N/A	N/A	N/A	1–5×104 104–106	N/A	2	ISt	MRI	0.5, 10	4% PFA	10, 21
62	Rabbit NZ	N/A	N/A	N/A	ICAO PPA	P	MRI	0	106 (1 μL)	N/A	4	ICe	MRI	5, 12, 15, 21	4% PFA	21
73	Rat Fisher	M	250	14/2	FOT1	N/A	N/A	N/A	106	N/A	1	ISt	MRI	4 h, 2, 7, 14	4% PFA	2, 6, 14
12	Rat SD	M	275–310	15/3	MCDA	T 30 T 60	N/A	N/A	5×104 (1 μL)	CC (20)	7	ISt (0.5; −0.5/3/−5)	MRI	2, 60	4% PFA	60
13	Rat Wistar	F	200–250	22/6	FOT2	N/A	N/A	N/A	2×104 2×106	CC (20)	2	IC EV	MRI	5, 12	2% TTC 4% PFA	0 1,5, 12
70	Rat SD	M	250–300	12/4	MCDA	T 120	NS	1	4×105 4×106	N/A	1	ISt (0.7/3/6.4) EV	MRI	1, 3, 7–28	4% PFA	28
68	Rat SD	M	200–250	16/N/A	MCDA	N/A	MRI	N/A	105 (2 μL)	N/A	7	ISt (l/−2/−4; or 0.5/3/−4)	MRI	2, 7–70	N/A	70
69	Rat Wistar	F	250–300	25/N/A	MCDA	T 120	LDF	0.5 h	106	N/A	30 min	IC EV	MRI	0, 2 h, 1	4% PFA	1
67	Mice	M	N/A	12/N/A	MCDA	T 60	MRI	14	5×102 or 5×103	N/A	1	ISt/IHp	MRI	1	GF	1
66	Rat Wistar	M	N/A	69/7	FOT2	N/A	N/A	N/A	2×105 2×106	CC	7	IC (−1/2.5/3.5) EV	MRI	14–49	4% PFA	14–49
74	Rat Wistar	M	260–300	14/2	MCDA	T 60	MRI	0–14	2×3×1a4	N/A	14	CCa/ISt (0.5/3/5)	MRI	0, 7, 14, 21	4% PFA	21

Note: The orientation of the grafting site was (AP/ML/DL).

Abbreviations: Ref, reference; SD, Sprague-Dawley; NZ, New Zealand; F, female; M, male; N/G, number of animals/group; OAF, femoral artery occlusion; MCDA, occlusion of the middle cerebral artery; CCO, occlusion of the common carotid artery; ICAO, occlusion of the internal carotid artery; FOT¹, photothrombosis model (rose Bengal 20 mg/kg, 20 min, 540 nm light); FOT², photothrombosis model (rose Bengal 10 mg/kg, 10 min, light 327–650 nm); OT, occlusion time; T, temporary; P, permanent; Mth, methods; MRI, magnetic resonance imaging; NS, neurological scale; Im, immunosuppression; CC, cyclosporine; Tp, time; min, minute; h, hour; ICe, intrahemisferic left; IHP, intrahippocampal; IC, intracortical; TTC, trifeniltetrazolium; PFA, paraformaldehyde; LDF, local default field test; EV, endovenous; ISt, intrastriatal; CCa, common carotid implantation; IHp, intrahippocampus; GF, 10% paraformaldehyde buffered with 5% gadoteridol; PPA, particles polyvinyl alcohol (150–250 μm); AG, angiography analyzed; N/A, not identified; AP, anteroposterior; ML, mediolateral; DV, dorsoventral.